Member Info for gtc1507

The company have just raised cash at no discount, large scale institutional buyers, and are secure for the medium term. Some excellent prospects, partnerships and closest to EBITDA positive they’ve ever been. Comparatively to their peers very cheap. I think it’s an excellent recovery play and for a micro cap with very few shares in issue, the technicals don’t always show the real picture. This has legs, they’re well respected in their field, have many assets in play. Yes CRO revenue can be lumpy but this feels like ahead excellent play at this point for me.

Might we finally see the trading update tomorrow? Be good to see the cash, margins and their vision for the rest of the year.

Sounds to me like you’re wishing it lower to come in Sax….

Not sure what your problem is saxman. History shows they tend to release their trading update last week of April or first week of May!

It’ll be a positive story to tell!!

Secured ~£1m from UKRI/Innovate UK and ~£545k from Launchpad R&D to progress the DR5 antibody program and proprietary platform technologies including® and OptiPhage™. Massively improves their margins and access to kit.

• DR5 agonist antibody (for treatment-resistant cancers) is grant-backed and targeted for licensing within 18 months; similar licensing deals in this space often include £5–20m+ upfronts and high double-digit royalties or milestones.

• Proprietary platforms (OptiMAL®, OptiPhage™, AI/ML-Ab™) are being positioned for external licensing; comparable platform providers generate >£10m p.a. through a mix of upfronts, FTE payments, milestones, and royalties.

• Completed a £1.17m equity raise in March 2025 at market price (6.75p, no discount), confirming strong institutional support and eliminating near-term funding risk.

• FY25 revenue expected to rise ~76% YoY to £2.0m, with gross margins rebounding to ~29% at H1 and analysts targeting >50% over time as high-margin tech ramps up.

• Expanded partnership with the U.S. National Cancer Institute (NCI) now includes nanobody humanisation, validating Fusion’s tech with a globally respected institution. Results are due any day.

• Fusion has last reported that they have 11 molecules in the clinic with embedded milestones/royalties – approaching FairJourney Biologics (14 molecules on their website) despite Fusion’s market cap (~£7m) being dwarfed by FJ’s recent €900m valuation.

• Absci (Nasdaq: ABSI), a U.S. AI-led discovery firm with similar platform ambitions, trades at over 50x Fusion’s valuation with a similar pre-commercial profile.

• Fusion’s diversified client base now spans diagnostics, veterinary and academic research, de-risking exposure to biotech funding cycles.

• Global services and IP licensing model makes it resilient to tariffs and trade barriers – low fixed cost base, high scalability.

• Analysts expected EBITDA-positive performance in FY26 – before accounting for recent grants, new revenue streams, or platform licensing upside….massive potential here IMO! DYOR

Very intrigued by the upcoming trading update.

How high will they have been able to recover the margins to. What was the final cash position bearing in mind they won’t have received tranche 2 of the raise.

Will be the true story of the recovery hopefully!

Also keen to hear about their strategy for this year and beyond and when we might get an update on Optimal, might it be timely to go into the update!

Couldn’t have been a sell at that price tho!

Decent buy in the auction? couldn’t sell anywhere near that level today so I’m thinking it must be

Update was last day of April last year?? Might we get good news next week?

I suspect the market waiting for their trading update to see the confirmation of recovery in 2024/25.

Also, platform validation news should be in short to medium term. Fab opportunity IMO!

Https://www.linkedin.com/posts/fusion-antibodies-plc_lsefab-fusion-antibodies-approval-of-activity-7321457570974433280-KbEd?utm_source=share&utm_medium=member_ios&rcm=ACoAAAuyH_0BZuiiVe69ogYIdwe7HKyUbPvkmaA

They want to licence the antibody in 18 months….some examples of the revenue generated by such deals.

Notable Preclinical Antibody Licensing Deals (2023–2025)

1. Nona Biosciences & AstraZeneca

• Date: May 2024

• Asset: Preclinical monoclonal antibodies for targeted tumor therapies

• Deal Value: $19 million upfront; up to $585 million in milestones

• Details: AstraZeneca entered into a global license and option agreement with Nona Biosciences to develop preclinical monoclonal antibodies into novel tumor-targeted therapies. Nona received $19 million upfront and is eligible for up to $575 million in development, regulatory, and commercial milestone payments, plus tiered royalties on net sales. 

2. Duality Biologics & GSK

• Date: December 2024

• Asset: Preclinical antibody-drug conjugate (ADC) targeting gastrointestinal cancer

• Deal Value: $30 million upfront; up to $975 million in milestones

• Details: GSK secured an exclusive option to license Duality Biologics’ preclinical ADC, DB-1324, for development and commercialization outside of mainland China, Hong Kong, and Macau. The agreement includes a $30 million upfront payment and potential milestone payments totaling up to $975 million, along with tiered royalties on net sales. 

3. Biomunex Pharmaceuticals & Ipsen

• Date: January 2025

• Asset: Preclinical T-cell engager for cancer immunotherapy

• Deal Value: Up to $610 million

• Details: Ipsen entered into an exclusive global licensing agreement with Biomunex Pharmaceuticals for a potentially first-in-class cancer immunotherapy. The deal includes upfront and milestone payments totaling up to $610 million, as well as tiered royalties on sales. 

4. FutureGen Biopharmaceutical & AbbVie

• Date: June 2024

• Asset: Preclinical anti-TL1A monoclonal antibody (FG-M701) for inflammatory bowel disease

• Deal Value: $150 million upfront; up to $1.56 billion in milestones

• Details: AbbVie licensed FG-M701, a fully human monoclonal antibody targeting TL1A, from FutureGen Biopharmaceutical for the treatment of inflammatory bowel disease. The agreement includes a $150 million upfront payment and potential milestone payments up to $1.56 billion, plus tiered royalties on net sales.  

5. Generate:Biomedicines & Novartis

• Date: September 2024

• Asset: AI-designed preclinical protein therapeutics

• Deal Value: $65 million upfront; over $1 billion in milestones

• Details: Novartis partnered with Generate:Biomedicines to leverage its generative AI platform for the discovery and development of protein therapeutics across multiple disease areas. The collaboration includes a $65 million upfront payment and potential performance-based milestone payments exceeding $1 billion, along with royalties on net sales.  

Https://www.ukri.org/news/northern-ireland-sees-big-rise-in-science-and-innovation-funding/

Some great interest just after midday!!

Https://www.irishnews.com/news/business/800000-grant-will-boost-fusion-project-to-develop-new-cancer-antibody-HQQVBMILVJCM7ESNAGYAF6LRTU/

Some amazing potential in this detailed video by the CSO. Here’s my summary:

Certainly — here’s the revised summary with key competitors referenced:

• Grant-backed development: Fusion Antibodies secured Innovate UK funding with Queen’s University Belfast to develop a clinic-ready anti-DR5 antibody over 18 months.

• Validated target, no approved drugs: DR5 is a well-established cancer target with active programs by AstraZeneca, Genmab, and Genentech, yet no antibodies have progressed to Phase 3 or received regulatory approval.

• Unique mechanism of action: Unlike competitors who use complex formats (e.g. AstraZeneca’s multivalent antibodies, Genmab’s hexameric constructs, and Genentech’s IgM mimetics), Fusion’s antibody naturally induces DR5 trimerization without external cross-linking.

• Proven superior efficacy: Fusion’s antibody shows significantly stronger cancer cell-killing ability in preclinical models than previous DR5 antibodies that failed and were discontinued.

• Licensing-focused strategy: Fusion intends to license the therapeutic asset to pharma/biotech partners post-development, reducing risk while monetising innovation.

• Platform promotion opportunity: The project doubles as a live demonstration of Fusion’s capabilities in antibody humanisation and GMP-ready cell line development, strengthening its commercial CRO offering.

“Richard breaks down why DR5 has long held promise in cancer treatment and explains why previous antibody candidates have struggled to progress beyond early-stage trials. He outlines the complexities of designing antibodies against this target and highlights what makes Fusion’s candidate structurally unique and potentially more effective.“

“With grant funding secured and Fusion’s humanisation expertise supporting preclinical development, the project is progressing toward key commercial milestones. Richard also discusses the opportunity to out-license the candidate to pharmaceutical partners and what success could look like for Fusion and its shareholders.”

Couple of accompanying videos on their hub!!

https://investorhub.fusionantibodies.com/announcements/6925611

https://investorhub.fusionantibodies.com/announcements/6925611

Massive news! 800k grant over 18 months to develop an antibody with QUB for sale. £500k for fusion! Massive news!! Shows how class they are!